Remdesivir was granted emergency use authorization last week by the US Food and Drug Administration for Covid-19, the highly contagious lung disease caused by the new coronavirus, and Gilead filed for fast-track approval in Japan on Monday. Moving forward, coordination on producing the drug will be "critical", the drugmaker says.
Gilead's also discussing long-term licensing deals with generics makers in India and Pakistan to produce the COVID-19 drug for the developing world.
Because the drug requires "scarce raw materials" to make, limitations to the supply chain could disrupt the amount of remdesivir produced.
Expectations are high that the drug can cure patients in serious condition.
O'Day declined to answer questions about whether Gilead plans to eventually profit from the COVID-19 treatment rather than just donate the medicine.
Gilead Sciences can only produce so much of its newly authorized COVID-19 drug remdesivir, so it's scouting other companies to bolster global supply.
Nicolas Cage to star as Joe Exotic in new show
The story also details his feud with Carole Baskin and Jeff Lowe , who were both featured in Netflix's Tiger King series. Variety reports that the scripted Joe Exotic series is being produced by Imagine Television and CBS Television Studios .
A trial performed by the U.S. Institutes of Health (NIH) showed the drug cut hospital stays by 31% compared with a placebo treatment, although it did not significantly improve survival.
US biopharmaceutical firm Gilead Sciences Inc. said Monday it applied with the Japanese health ministry for approval to use its anti-viral drug remdesivir to treat new coronavirus patients, paving the way for its clearance as early as this week.
Dr Anthony Fauci, the nation's top infectious disease expert, said although the results weren't a 'knock out 100 percent, ' it was an important proof of concept.
'This is very optimistic, the mortality rate trended towards being better in the sense of less deaths in the REM designate group.
To further facilitate access in developing countries during this acute health crisis, Gilead is in advanced discussions with UNICEF to utilise their vast experience in providing medicines to low- and middle-income countries during emergency and humanitarian crises to deliver remdesivir using its distribution networks.